28th Apr 2017 16:54
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | |||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | PROTEOME SCIENCES PLC | ||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | YES | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
An event changing the breakdown of voting rights | |||||
Other (please specify): | |||||
3. Full name of person(s) subject to thenotification obligation: iii | VULPES LIFE SCIENCES FUND VULPES TESTUDO FUND
| ||||
4. Full name of shareholder(s) (if different from 3.):iv | |||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 27 APRIL 2017 | ||||
6. Date on which issuer notified: | 28 APRIL 2017 | ||||
7. Threshold(s) that is/are crossed orreached: vi, vii | >18% | ||||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
GB0003104196 | 53,943,715 | 53,943,715 | 54,043,715 | 54,043,715 | 18.34% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
54,043,715 | 18.34% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | ||
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: |
| |
14. Contact name: | Victoria Birse | |
15. Contact telephone number: | ||
Note: Annex should only be submitted to the FCA not the issuer | |
Annex: Notification of major interests in share | |
A: Identity of the persons or legal entity subject to the notification obligation | |
Full name (including legal form of legal entities)
| VULPES LIFE SCIENCES FUND |
Contact address (registered office for legal entities)
| c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands |
Phone number & email
| |
Other useful information (at least legal representative for legal persons)
| |
B: Identity of the notifier, if applicable | |
Full name
| Stephen Diggle |
Contact address
| One George Street #07-03 Singapore 049145
|
Phone number & email
| Tel: (65) 6538 1998 (Main) Email: [email protected] |
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) | Director |
C: Additional information | |
Email address: Complete the required TR-1 form and email it to: Major shareholdings [email protected] Fax number: You can print the TR-1 form, complete it and fax it to: 020 7066 0050 | |
For notes on how to complete form TR-1 please see the FCA website. |
Related Shares:
Proteome